Akiko Serizawa

Akiko Serizawa

Auto-generated profile, based on publicly available information

Akiko Serizawa

Department of Surgery, Fujita Health University, Toyoake, Japan

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2022 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
KMKazuhiro Matsuo
Kazuhiro Matsuo
SSSusumu Shibasaki
Susumu Shibasaki
KSKazumitsu Suzuki
Kazumitsu Suzuki
ASAkiko Serizawa
Akiko Serizawa
SAShingo Akimoto
Shingo Akimoto
KSKoichi Suda
Koichi Suda

7 August 2018 in Surgical Case Reports
Verified
Journal Article
Open access
PDF file
ASAkiko Serizawa
Akiko Serizawa
KTKiyoaki Taniguchi
Kiyoaki Taniguchi
TYTakuji Yamada
Takuji Yamada
KAKunihiko Amano
Kunihiko Amano
SKSho Kotake
Sho Kotake
Masakazu YamamotoMasakazu Yamamoto
Masakazu Yamamoto
Although patients with stage IV gastric cancer who respond well to systemic chemotherapy can be treated with gastrectomy, the prognosis of patients with unresectable gastric cancer with para-aortic lymph node metastasis is poor. We herein report a case of remnant gastric cancer with para-aortic lymph node metastasis that was treated with potentially curative conversion surgery after showing a complete response to chemotherapy with S-1 and oxaliplatin (SOX). An 81-year-old man was diagnosed with type 3 remnant gastric cancer with giant para-aortic lymph node metastasis, and he received SOX chemotherapy. After three courses of SOX chemotherapy, the primary tumor and para-aortic lymph node metastases markedly reduced in size, indicating a partial response. Because conversion surgery was possible, the patient underwent total remnant gastrectomy with D2 and para-aortic lymph node dissection. Histological examination revealed no residual cancer cells in the resected stomach and lymph nodes. The patient was diagnosed with a complete pathological response and was discharged on postoperative day 24. Currently, 1 year after surgery, the patient is alive and has not shown any tumor recurrence. To the best of our knowledge, this is the first case of advanced remnant gastric cancer with giant para-aortic lymph node metastasis that showed a pathological complete response and favorable outcome after SOX chemotherapy.

19 September 2023 in Langenbeck's Archives of Surgery
Verified
Journal Article
Closed access
PDF file
MFMasahiro Fujita
Masahiro Fujita
MNMasaya Nakauchi
Masaya Nakauchi
KSKazumitsu Suzuki
Kazumitsu Suzuki
ASAkiko Serizawa
Akiko Serizawa
SAShingo Akimoto
Shingo Akimoto
KSKoichi Suda
Koichi Suda

21 May 2024 in Asian Journal of Endoscopic Surgery
Verified
Journal Article
Closed access
MFMasahiro Fujita
Masahiro Fujita
MNMasaya Nakauchi
Masaya Nakauchi
MIMasamoto Iida
Masamoto Iida
KKKeisuke Koide
Keisuke Koide
SISeiji Inoue
Seiji Inoue
KSKoichi Suda
Koichi Suda

29 April 2021 in Research Square
Verified
Preprint
Open access
PDF file
ASAkiko Serizawa
Akiko Serizawa
HKHidekazu Kuramochi
Hidekazu Kuramochi
KTKiyoaki Taniguchi
Kiyoaki Taniguchi
MOMasaho Ota
Masaho Ota
SKSatoshi Katagiri
Satoshi Katagiri
MYMasakazu Yamamoto
Masakazu Yamamoto
Background: In Japan, the standard treatment for stage II or III gastric cancer is D2 gastrectomy followed by administration of S-1 for one year. However, patients with stage III disease have unsatisfactory survival rates. The purpose of this study was to evaluate the efficacy and safety of neoadjuvant chemotherapy consisting of S-1 and oxaliplatin for advanced gastric cancer.Methods: Patients with cT4 or cN2–3 gastric cancer were scheduled to receive two courses of chemotherapy (130 mg/m2 oxaliplatin on Day 1, 80 mg/m2 S-1 per day twice daily for 14 days) followed by surgery. The primary endpoint was the R0 resection rate. The secondary endpoints were rates of completion of protocol treatment, pathological response, and adverse events; and 3-year overall survival, 5-year overall survival, and 5-year recurrence-free survival.Results: Between May 2016 and March 2019, 30 patients were enrolled in the study, all of whom completed the protocol treatment. The R0 resection rate (primary endpoint) was 93.3% (95% confidence interval: 77.9–99.2). The pathological response rate was 63.3%. Grade 3–4 toxicities included anemia (3.3%), anorexia (6.7%), and fatigue (3.3%). Relative dose intensities were 91.2% and 94.2% for S-1 and oxaliplatin, respectively.Conclusions: Neoadjuvant S-1 and oxaliplatin is highly effective, achieving an acceptable R0 resection rate with relatively few severe toxicities and good compliance. Trial registration information:Registry name: A prospective intervention study on the availability of preoperative SOX therapy for T4 or N2-3 gastric cancerTrial ID: UMIN: UMIN000024656URL: https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000028365